Enovis Beats Q2 Estimates, Reaffirms 2026 Outlook
ENOV sits 58% above its 52-week low of $19.14.
Summary
Enovis posted Q2 sales of $582.78M, edging past the $582.54M consensus, while adjusted EPS of $0.90 beat the $0.85 estimate. Gross margin came in at 61.6%. The Reconstructive segment drove growth, up 8% reported and 6% organically, reflecting new product momentum and improved commercial execution. Management reaffirmed full-year 2026 guidance, including revenue of $2.31B-$2.37B and adjusted EPS of $3.52-$3.73. The beat and steady outlook provide modest positive momentum, though the slight revenue beat and unchanged guidance may limit upside surprise.
At the time of this announcement, ENOV was trading at $30.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $19.14 to $34.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.